Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Thursday, October 6, 2022 · 594,445,564 Articles · 3+ Million Readers

At 14.7 % CAGR, Antibody Drug Conjugate Market Size Worth USD 10.32 Billion by 2027: IndustryARC

Antibody Drug Conjugate Market

Market Research Reports, Business Consulting Services & Analytics

Surging Applications Of Monoclonal Antibodies Are Projected To Drive The Growth Of Antibody Drug Conjugate Market

HYDERABAD, TELANGANA, INDIA, September 22, 2022 /EINPresswire.com/ -- IndustryARC, in its latest report, predicts that Antibody Drug Conjugate Market size is estimated to reach $10.32 billion by 2027, growing at a CAGR of 14.7% during the forecast period 2022-2027. Antibody-Drug Conjugate indicates monoclonal antibodies conjugated to cytotoxic agents. It utilizes antibodies that are particular to tumor cell-surface proteins and therefore, possess tumor particularity and efficacy unattainable with conventional medications. The report offers a complete analysis of the market, its major segments, growth factors, trends, drivers and challengers, key players and more.


Click here to browse the complete report summary:
https://www.industryarc.com/Report/15696/antibody-drug-conjugate-market.html


Key Takeaways:

This IndustryARC report on the Antibody Drug Conjugate Market highlights the following areas -

1. Geographically, North America Antibody Drug Conjugate Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of cancer resulting in heightened awareness of cancer and the upsurge in the application of antibody-drug conjugate involving monoclonal antibodies amidst the population in the North American region.

2. Antibody Drug Conjugate Market growth is being driven by the rising pervasiveness of cancer, the surging application of antibody-drug conjugate involving monoclonal antibodies, and the surging R&D activities for the evolution of new therapeutics. However, the binding government regulations, the soaring cost of procedures, and the dearth of funds are some of the major factors hampering the growth of the Antibody Drug Conjugate Market.

3. Antibody Drug Conjugate Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Antibody Drug Conjugate Market report


Interested in knowing more relevant information? Click here:
https://www.industryarc.com/pdfdownload.php?id=15696


Segmental Analysis:

1. The Antibody Drug Conjugate Market based on product type can be further segmented into Adcetris, Kadcyla, and Others. The Kadcyla Segment held the largest market share in 2021. This growth is owing to the increasing application of KADCYLA as targeted therapy and prescription medication utilized as an adjuvant (consequent to surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (prior to surgery) treatment inclusive of a taxane and trastuzumab (Herceptin ®) and there is cancer remaining in the tissue eliminated at the time of surgery. The enhanced survival rate in HER2-positive patients is further propelling the growth of the Kadcyla segment.

2. The Antibody Drug Conjugate Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Antibody Drug Conjugate Market) held the largest share with 37% of the overall market in 2021. The growth of this region is owing to the extensive augmentation of ingenious technologies in U.S., Canada, and Mexico in the region.

3. The Antibody Drug Conjugate Market based on the application can be further segmented into Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others. The Breast Cancer Segment held the largest market share in 2021. This growth is owing to the increasing predominance of breast cancer worldwide.


Competitive Landscape:

The top 5 players in the Antibody Drug Conjugate industry are -

1. Seagen Inc.
2. ImmunoGen Inc.
3. Mersana Therapeutics
4. Pfizer Inc.
5. F Hoffmann-La Roche Ltd


Click on the following link to buy the Antibody Drug Conjugate Market report:
https://www.industryarc.com/reports/request-quote?id=15696


Why Choose IndustryARC?

IndustryARC is one of the leading market research and consulting firms in the world. It produces over 500 unique market reports annually. If you are looking for a detailed overview of a particular market, you can simply connect with the team at IndustryARC. You can not only buy your preferred market report from the website, but also get personalized assistance on specific reports.


Similar Reports:

A. Antibody Testing Market
https://www.industryarc.com/Report/19287/antibody-testing-market.html

B. Immunohistochemistry Market
https://www.industryarc.com/Report/16715/immunohistochemistry-market.html


Contact Us:
Mr. Venkat Reddy
IndustryARC
Email: sales@industryarc.com
USA: (+1) 970-236-3677, (+1) 815-656-4596
IND: (+91) 40-485-49062

Venkat Reddy
IndustryARC
+1 614-588-8538
venkat@industryarc.com
Visit us on social media:
Facebook
Twitter
LinkedIn

Powered by EIN Presswire
Distribution channels: Healthcare & Pharmaceuticals Industry


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release